Technology | August 11, 2009

Pathway Medical Technologies Introduces Jetstream G2 NXT Atherectomy Catheter

August 11, 2009 – Pathway Medical Technologies Inc. today introduced the 7 French compatible version of its peripheral atherectomy catheter, the Jetstream G2 NXT.

The catheter is based on the company’s catheter technology capable of treating the entire spectrum of disease found in patients suffering from peripheral artery disease (PAD), including hard and soft plaque, calcium, fibrotic lesions and thrombus. The 7 Fr. compatibility allows physicians to use Jetstream G2 NXT in the treatment of PAD in a more diverse patient population, significantly expanding the number of patients who can now benefit from this innovative technology, the company said.

“The 7 Fr. compatible Jetstream G2 NXT is nearly identical to Jetstream G2, but has the advantages associated with smaller sheath technology,” said Dr. Robert Bersin at Seattle Cardiology. “As such, it expands my ability to treat more anatomies and patients with varying degrees of PAD.”

Jetstream G2 NXT is a peripheral atherectomy catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. This innovative and minimally invasive solution clears blockages in the peripheral vasculature, restores blood flow and effectively treats PAD.

Jetstream G2 NXT consists of a sterile, single-use catheter and control pod and a reusable, compact console that mounts to a standard I.V. stand. The catheter has an expandable cutting tip that safely debulks and preemptively removes both hard and soft plaque, as well as calcium, thrombus and fibrotic lesions. A highly efficient aspiration port located just proximal to the cutting blades continually removes excised tissue and thrombus from the treatment site to a collection bag located on the console. The distal portion of the catheter also possesses infusion ports that provide continuous infusion of sterile saline during the atherectomy procedure. Active aspiration is a safety feature that minimizes the risk of distal embolization.

For more information: www.pathwaymedical.com

Related Content

News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
Covidien, Medtronic, TurboHawk, Atherectomy system

The Medtronic TurboHawk atherectomy system. 

Feature | Atherectomy Devices| August 18, 2016 | Dave Fornell
Due to poor outcomes from percutaneous transluminal angioplasty (PTA) ballooning of vessels alone, or of stenting in
Cardiovascular Systems Inc., LIBERTY 360 study, Amputation Prevention Symposium, PAD, peripheral artery disease, atherectomy
News | Peripheral Arterial Disease (PAD)| August 16, 2016
August 16, 2016 — Cardiovascular Systems Inc.
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral| August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters| July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
News | Drug-Eluting Balloons| June 03, 2016
June 3, 2016 — Cardionovum GmbH recently announced the completion of enrollment of the RAPID trial.
CSI, Cardiovascular Systems Inc, Diamondback 360 Coronary Orbital Atherectomy System, OAS, ORBIT II study, three-year results, SCAI 2016
News | Atherectomy Devices| May 06, 2016
May 6, 2016 — Cardiovascular Systems Inc.
TOBA-BTK study, twelve-month results, SCAI 2016, Tack Endovascular System, critical limb ischemia
News | Peripheral Arterial Disease (PAD)| May 05, 2016
Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-...
Overlay Init